Advaxis, Inc. - Product Pipeline Review - 2016 Summary Global Markets Direct's, ‘Advaxis, Inc. - Product Pipeline Review - 2016', provides an overview of the Advaxis, Inc.'s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Advaxis, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of Advaxis, Inc. - The report provides overview of Advaxis, Inc. including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses Advaxis, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features Advaxis, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons to Buy - Evaluate Advaxis, Inc.'s strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Advaxis, Inc. - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Advaxis, Inc.'s pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Table of Content
Table of Contents 2 List of Tables 5 List of Figures 5 Advaxis, Inc. Snapshot 6 Advaxis, Inc. Overview 6 Key Information 6 Key Facts 6 Advaxis, Inc. - Research and Development Overview 7 Key Therapeutic Areas 7 Advaxis, Inc. - Pipeline Review 10 Pipeline Products by Stage of Development 10 Pipeline Products - Monotherapy 11 Advaxis, Inc. - Pipeline Products Glance 12 Advaxis, Inc. - Clinical Stage Pipeline Products 12 Phase II Products/Combination Treatment Modalities 12 Phase I Products/Combination Treatment Modalities 13 Advaxis, Inc. - Early Stage Pipeline Products 14 Preclinical Products/Combination Treatment Modalities 14 Advaxis, Inc. - Drug Profiles 15 axalimogene filolisbac 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 ADXS-HER2 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 ADXS-PSA 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 Adxs-LmddA159 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 ADXS-NEO 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 ADXS-TNBC 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 Lm-LLO-CA9 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 Lm-LLO-CD105A 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 Lm-LLO-Flk1 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 Lm-LLO-HMWMAAC 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Lm-LLO-ISG15 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Lovaxin S 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 Vaccine to Target CEA for Ovarian Cancer 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 Vaccine to Target FAP for Breast and Colorectal Cancer 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Vaccine to Target HER2 and CA9 for Breast Cancer 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 Vaccine to Target Her2 and HMWMAA for Breast Cancer 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 Vaccine to Target IL-13R Alpha2 for Solid Tumor 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 Vaccine to Target PSA and HMWMAA for Prostate Cancer 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 Vaccine to Target PSCA for Prostate Cancer 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 Vaccine to Target WT1 for Oncology 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 Advaxis, Inc. - Pipeline Analysis 55 Advaxis, Inc. - Pipeline Products by Target 55 Advaxis, Inc. - Pipeline Products by Route of Administration 57 Advaxis, Inc. - Pipeline Products by Molecule Type 58 Advaxis, Inc. - Recent Pipeline Updates 59 Advaxis, Inc. - Dormant Projects 75 Advaxis, Inc. - Company Statement 76 Advaxis, Inc. - Company Statement 76 Advaxis, Inc. - Locations And Subsidiaries 80 Head Office 80 Appendix 81 Methodology 81 Coverage 81 Secondary Research 81 Primary Research 81 Expert Panel Validation 81 Contact Us 81 Disclaimer 82
List of Tables
Advaxis, Inc., Key Information 6 Advaxis, Inc., Key Facts 6 Advaxis, Inc. - Pipeline by Indication, 2016 8 Advaxis, Inc. - Pipeline by Stage of Development, 2016 10 Advaxis, Inc. - Monotherapy Products in Pipeline, 2016 11 Advaxis, Inc. - Phase II, 2016 12 Advaxis, Inc. - Phase I, 2016 13 Advaxis, Inc. - Preclinical, 2016 14 Advaxis, Inc. - Pipeline by Target, 2016 55 Advaxis, Inc. - Pipeline by Route of Administration, 2016 57 Advaxis, Inc. - Pipeline by Molecule Type, 2016 58 Advaxis, Inc. - Recent Pipeline Updates, 2016 59 Advaxis, Inc. - Dormant Developmental Projects,2016 75
List of Figures
Advaxis, Inc. - Pipeline by Top 10 Indication, 2016 8 Advaxis, Inc. - Pipeline by Stage of Development, 2016 10 Advaxis, Inc. - Monotherapy Products in Pipeline, 2016 11 Advaxis, Inc. - Pipeline by Top 10 Target, 2016 55 Advaxis, Inc. - Pipeline by Route of Administration, 2016 57 Advaxis, Inc. - Pipeline by Molecule Type, 2016 58
Global non destructive testing equipment market is anticipated to reach USD 5.76 billion by 2022, as per a new research report by Radiant Insights, Inc. Stringent government safety initiatives for inspection and quality control across numerous industRead More...
Global fluorotelomers market size is anticipated to be valued at USD 539.3 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing application scope in fire fighting systems owing to growing safety concerns is likely to driRead More...
Global Automated Test Equipment (ATE) market is expected to be valued at USD 4.48 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing design complexity coupled with need for effective testing is expected to drive the glRead More...
Global lignin market size is expected to exceed USD 6 billion by 2022, growing at 4.9% from 2015 to 2022. Rising demand for animal feed and potential as a feedstock substitute to crude oil are expected to drive lignin market demand over the forecastRead More...
Global compressed air treatment equipment market is projected to reach USD 8.59 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing implementation of this equipment in various industry sectors such as healthcare & pharmaceRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.